| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.094 | 0.004 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | 0.12 | 0.005 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.006 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | 0.13 | 0.006 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.099 | 0.006 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.09 | 0.007 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.1 | 0.008 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.084 | 0.008 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.077 | 0.009 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | 0.084 | 0.009 |